CN105120900A - 用于治疗慢性炎症和炎性疾病的组合物及方法 - Google Patents

用于治疗慢性炎症和炎性疾病的组合物及方法 Download PDF

Info

Publication number
CN105120900A
CN105120900A CN201480006334.8A CN201480006334A CN105120900A CN 105120900 A CN105120900 A CN 105120900A CN 201480006334 A CN201480006334 A CN 201480006334A CN 105120900 A CN105120900 A CN 105120900A
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
oil
pharmaceutical composition
fatty acid
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480006334.8A
Other languages
English (en)
Chinese (zh)
Inventor
罗宾·马克·班尼斯特
约翰·布鲁
威尔逊·卡帕罗斯-万德莱
苏珊妮·简·迪利
奥尔加·普莱格苏埃洛斯马泰奥
格雷戈里·艾伦·斯托洛弗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biocopea Ltd
Original Assignee
Biocopea Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocopea Ltd filed Critical Biocopea Ltd
Publication of CN105120900A publication Critical patent/CN105120900A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201480006334.8A 2013-02-04 2014-01-14 用于治疗慢性炎症和炎性疾病的组合物及方法 Pending CN105120900A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361752309P 2013-02-04 2013-02-04
US61/752,309 2013-02-04
PCT/EP2014/050627 WO2014117999A1 (en) 2013-02-04 2014-01-14 Compositions and methods for treating chronic inflammation and inflammatory diseases

Publications (1)

Publication Number Publication Date
CN105120900A true CN105120900A (zh) 2015-12-02

Family

ID=50150686

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480006334.8A Pending CN105120900A (zh) 2013-02-04 2014-01-14 用于治疗慢性炎症和炎性疾病的组合物及方法

Country Status (14)

Country Link
EP (1) EP2950821A1 (https=)
JP (1) JP6474352B2 (https=)
KR (1) KR20150129664A (https=)
CN (1) CN105120900A (https=)
AU (1) AU2014211715B2 (https=)
BR (1) BR112015015870B1 (https=)
CA (1) CA2898017A1 (https=)
HK (1) HK1218621A1 (https=)
IL (1) IL239920A0 (https=)
MX (1) MX366317B (https=)
RU (1) RU2680801C2 (https=)
SG (1) SG11201505243PA (https=)
WO (1) WO2014117999A1 (https=)
ZA (1) ZA201505006B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108283637A (zh) * 2018-04-04 2018-07-17 无锡市儿童医院 辛伐他汀的应用

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US8895536B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating chronic inflammation and inflammatory diseases
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
EP3313519B1 (en) * 2015-06-29 2023-05-31 Children's Medical Center Corporation Jak-stat inhibitors for the treatment of congenital myopathies
WO2019195943A1 (en) * 2018-04-13 2019-10-17 Urban Juve Provisions Inc. Cannabis root extract, method of manufacture, method of use
JP2022534783A (ja) * 2019-06-03 2022-08-03 イミュノルクス インターナショナル コーポレーション 疾患を処置するための天然痘ワクチン及び幹細胞
US20220378729A1 (en) * 2019-11-06 2022-12-01 Smartech Topical, Inc. Topical formulations of cyclooxygenase inhibitors and their use
RU2749857C1 (ru) * 2019-12-23 2021-06-17 Псарева Нелли Александровна Способ борьбы со средним и наружным отитом
RU2752764C1 (ru) * 2020-12-14 2021-08-03 Общество с ограниченной ответственностью "Тривиум-ХХI" (ООО "Тривиум-ХХI") Фармацевтическая композиция, обладающая противовоспалительным действием
EP4312978A2 (en) 2021-03-27 2024-02-07 TRX Biosciences Limited Compositions having improved bioavailability of therapeutics
RU2760220C1 (ru) * 2021-06-02 2021-11-22 Федеральное государственное бюджетное научное учреждение «Научно-исследовательский институт ревматологии имени В.А. Насоновой» (ФГБНУ НИИР им. В.А. Насоновой) Способ определения клинически значимой усталости у больного ревматоидным артритом на фоне 5-летней терапии базисными противовоспалительными препаратами или базисными противовоспалительными препаратами в комплексе с генно-инженерными биологическими препаратами и/или психофармакотерапией и сопутствующего расстройства тревожно-депрессивного спектра
WO2025122472A1 (en) * 2023-12-04 2025-06-12 Primus Pharmaceuticals, Inc. Emollient compositions comprising linoleic acid and conjugated linoleic acid and methods of use

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2331458A (en) * 1997-11-21 1999-05-26 Gursharan Singh Moonga Solvent compositions for gelatin capsules
WO2000076478A1 (en) * 1999-06-14 2000-12-21 Cosmo S.P.A. Controlled release and taste masking oral pharmaceutical compositions
US20100099767A1 (en) * 2007-03-13 2010-04-22 Adrian Francis Davis Topical Pharmaceutical Formulation
WO2012104655A2 (en) * 2011-02-04 2012-08-09 Biocopea Limited Compostions and methods for treating chronic inflammation and inflammatory diseases

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143934A (en) * 1990-11-21 1992-09-01 A/S Dumex (Dumex Ltd.) Method and composition for controlled delivery of biologically active agents
GB9613858D0 (en) * 1996-07-02 1996-09-04 Cortecs Ltd Hydrophobic preparations
ATE265847T1 (de) * 1997-07-29 2004-05-15 Upjohn Co Selbstemulgierbare formulierung enthaltend lipophile verbindungen
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
KR20020011985A (ko) * 1999-05-07 2002-02-09 파르마솔 게엠베하 액상 및 고체상 지질 혼합물에 기초한 지질입자들 및 그의제조방법
MXPA01011343A (es) * 1999-05-07 2002-06-04 Pharmasol Gmbh Particulas de lipidos a base de mezclas de lipidos liquidos y solidos asi como procedimiento para su produccion.
US6455067B1 (en) * 2000-05-24 2002-09-24 Sang-A Pharmaceutical Co., Ltd. Transdermal patch for nonsteroidal antiinflammatory drug(s)
US20030105141A1 (en) * 2001-04-17 2003-06-05 Ping Gao Finely self-emulsifiable pharmaceutical composition
RU2319508C2 (ru) * 2003-07-31 2008-03-20 ФАРМАЦИЯ ЭНД АПДЖОН КОМПАНИ ЭлЭлСи Диспергируемый препарат противовоспалительного агента
MX2007006183A (es) * 2004-11-24 2007-09-11 Merck & Co Inc Formulaciones farmaceuticas liquidas y semisolidas para administracion oral de una amida sustituida.
US20060138059A1 (en) 2004-12-28 2006-06-29 Vair Larry L Jr Corona-treated polypropylene liquid filtration media
KR20080023677A (ko) * 2005-04-28 2008-03-14 갈레니카 테크놀로지 아베 지질상을 포함하는 약학적 투약 형태
US20070249725A1 (en) * 2006-02-17 2007-10-25 Hubbard David R Pharmaceutical formulations of sympathetic antagonist for the treatment of chronic muscle pain
EP2310371B1 (fr) 2008-05-26 2013-05-15 Genfit Composés agonistes ppar, préparation et utilisations pour le traitement du diabète et/ou des dyslipidémies

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2331458A (en) * 1997-11-21 1999-05-26 Gursharan Singh Moonga Solvent compositions for gelatin capsules
WO2000076478A1 (en) * 1999-06-14 2000-12-21 Cosmo S.P.A. Controlled release and taste masking oral pharmaceutical compositions
US20100099767A1 (en) * 2007-03-13 2010-04-22 Adrian Francis Davis Topical Pharmaceutical Formulation
WO2012104655A2 (en) * 2011-02-04 2012-08-09 Biocopea Limited Compostions and methods for treating chronic inflammation and inflammatory diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
E. CSIZMAZIA，ET AL: ""Penetration enhancer effect of sucrose laurate and Transcutol"", 《JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108283637A (zh) * 2018-04-04 2018-07-17 无锡市儿童医院 辛伐他汀的应用

Also Published As

Publication number Publication date
HK1218621A1 (zh) 2017-03-03
MX2015009058A (es) 2016-01-08
BR112015015870A8 (pt) 2018-01-16
AU2014211715B2 (en) 2016-08-25
EP2950821A1 (en) 2015-12-09
AU2014211715A1 (en) 2015-07-23
MX366317B (es) 2019-07-03
BR112015015870A2 (pt) 2017-07-11
SG11201505243PA (en) 2015-08-28
CA2898017A1 (en) 2014-08-07
JP2016506941A (ja) 2016-03-07
WO2014117999A1 (en) 2014-08-07
BR112015015870B1 (pt) 2022-09-27
ZA201505006B (en) 2016-03-30
JP6474352B2 (ja) 2019-02-27
IL239920A0 (en) 2015-08-31
RU2015137659A (ru) 2017-03-10
KR20150129664A (ko) 2015-11-20
RU2680801C2 (ru) 2019-02-27

Similar Documents

Publication Publication Date Title
US12533332B2 (en) Compositions and methods for treating chronic inflammation and inflammatory diseases
US10653778B2 (en) Compositions and methods for treating chronic inflammation and inflammatory diseases
CN105120900A (zh) 用于治疗慢性炎症和炎性疾病的组合物及方法
CN103391768B (zh) 治疗慢性炎症和炎性疾病的组合物和方法
NZ613812B2 (en) Compositions and methods for treating chronic inflammation and inflammatory diseases

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20151202

RJ01 Rejection of invention patent application after publication